Danaher Corporation DHR
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Danaher Corporation is a large-cap company in the Healthcare sector (Diagnostics & Research), with a market value of $150.5B, based in the USA.
It employs about 58,000 people and has been listed since Jan 05, 1979.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 37.8 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 6% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 23.8 — they expect higher earnings.
The average analyst price target is 234.73, 10% above the current price (their view, not ours).
The stock sits at 66% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 14 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (2% fewer shares in a year).
- ✅ Most analysts rate it buy (22 vs 0).
- ✅ Pays a dividend (0.7% a year).
What changed this week
Over the past week the stock fell 4.5% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- CPM Names Jeremy Patten Chief Executive Officer finance.yahoo.com · 2026-10-02
- Parker-Hannifin Benefits From Business Strength Amid Headwinds finance.yahoo.com · 2026-10-02
- Perimeter Medical Imaging AI Appoints Finance Executive Michelle Caron to Board of Directors finance.yahoo.com · 2026-10-02
- Why Danaher (DHR) Shares Are Trading Lower Today finance.yahoo.com · 2026-10-01
- Q2 Earnings Review: Research Tools & Consumables Stocks Led by Avantor (NYSE:AVTR) finance.yahoo.com · 2026-10-01
- Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.